Literature DB >> 6362411

Review: the cerebrohepatorenal syndrome of Zellweger, morphologic and metabolic aspects.

R I Kelley.   

Abstract

The cerebrohepatorenal syndrome of Zellweger (CHRS) is remarkable not only for a distinctive combination of congenital anomalies, but also for an unusual variety of profound metabolic disturbances. After a discussion of the clinical diagnosis of CHRS, abnormalities in the metabolism of peroxisomes, mitochondria, iron, pipecolic acid, glycogen, bile acids, and organic acids are discussed and related to the clinical and other biochemical findings in the syndrome. Attention is also drawn to syndromes with biochemical or clinical abnormalities similar to those of CHRS. Although the biochemical findings indicate major abnormalities in oxidative metabolism, the primary defect remains obscure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6362411     DOI: 10.1002/ajmg.1320160409

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  44 in total

1.  Study of peroxisomal proteins in patients with Zellweger syndrome.

Authors:  J Gärtner; A Balfe; W W Chen; H W Moser
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

Review 2.  Antenatal manifestations of inborn errors of metabolism: autopsy findings suggestive of a metabolic disorder.

Authors:  Sophie Collardeau-Frachon; Marie-Pierre Cordier; Massimiliano Rossi; Laurent Guibaud; Christine Vianey-Saban
Journal:  J Inherit Metab Dis       Date:  2016-04-22       Impact factor: 4.982

3.  Infantile Refsum disease: deficiency of catalase-containing particles (peroxisomes), alkyldihydroxyacetone phosphate synthase and peroxisomal beta-oxidation enzyme proteins.

Authors:  R J Wanders; R B Schutgens; G Schrakamp; H van den Bosch; J M Tager; A W Schram; T Hashimoto; B T Poll-Thé; J M Saudubrau
Journal:  Eur J Pediatr       Date:  1986-08       Impact factor: 3.183

4.  Partial deficiency of dihydroxyacetone phosphate acyltransferase activity in both classical and infantile Refsum's diseases.

Authors:  J T Van Crugten; B Paton; A Poulos
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

Review 5.  Peroxisomal disorders: clinical characterization.

Authors:  L Monnens; H Heymans
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

6.  Attenuated prostaglandin formation in peroxisomal-deficient human skin fibroblasts.

Authors:  J A Gordon; L J Warnock; A A Spector
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Presence of the peroxisomal 22-kDa integral membrane protein in the liver of a person lacking recognizable peroxisomes (Zellweger syndrome).

Authors:  P B Lazarow; Y Fujiki; G M Small; P Watkins; H Moser
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  Neuronal lipidosis and neuroaxonal dystrophy in cerebro-hepato-renal (Zellweger) syndrome.

Authors:  J M Powers; R C Tummons; A B Moser; H W Moser; D S Huff; R I Kelley
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

9.  Peroxisomal fatty acid beta-oxidation in relation to the accumulation of very long chain fatty acids in cultured skin fibroblasts from patients with Zellweger syndrome and other peroxisomal disorders.

Authors:  R J Wanders; C W van Roermund; M J van Wijland; R B Schutgens; J Heikoop; H van den Bosch; A W Schram; J M Tager
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

10.  Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions.

Authors:  Soumya Raychaudhuri; Robert M Plenge; Elizabeth J Rossin; Aylwin C Y Ng; Shaun M Purcell; Pamela Sklar; Edward M Scolnick; Ramnik J Xavier; David Altshuler; Mark J Daly
Journal:  PLoS Genet       Date:  2009-06-26       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.